REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.…
Regenxbio Inc (RGNX) (Q3 2026) Earnings Call Highlights: Dual Gene Therapy Catalysts Near ...
REGENXBIO (NASDAQ: RGNX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 371 employees.
The shares were at 7.160 USD on 20 November 2026, down 35.9% over 52 weeks. Its 52-week range is 5.455 USD to 16.19 USD: the price is 55.8% below the high and 31.3% above the low.
Its market capitalisation is 473.44M USD.
REGENXBIO reports return on equity of -188.7%, an operating margin of -120.4% and revenue down 69.2% year over year.
Its debt exceeds its cash by 1.25M USD, a debt-to-equity ratio of 0.72. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 10 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 21.40 USD is 198.9% above the current price. The next earnings report is expected on 4 March 2027.